Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 348-353

  Buzdar, Aman U ^a,b   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TOREMIFENE;

ANOREXIA; ASTHENIA; BREAST CARCINOMA; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG STRUCTURE; ENDOMETRIUM CARCINOMA; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HYPOCHOLESTEROLEMIA; INSOMNIA; LIVER CARCINOMA; METASTASIS; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; VAGINITIS;

EID: 0031962302     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.348     Document Type: Review

References (29)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
2. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A:576-588, 1996
3. Kangas L: Introduction to toremifene. Breast Cancer Res Treat 16:S3-S7, 1990 (suppl)
4. Kangas L: Review of the pharmacological properties of toremifene. J Steroid Biochem 36:191-195, 1990
5. Tominaga T, Yoshida Y, Matsumoto A, et al: Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro. Anticancer Res 13:661-666, 1993
6. Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541, 1993
7. Guzelian PS: Relevance of rat liver tumors to human hepatic and endometrial cancer. Semin Oncol 24:s1-105-s1-121, 1997 (suppl 1)
8. Styles JA, Davies A, Lim CK, et al: Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15:5-9, 1994
9. Dragan YP, Vaughan J, Jordan VC, et al: Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16:2733-2741, 1995
10. White INH, de Matteis F, Davies A, et al: Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203, 1992
11. Phillips DH, Carmichael PL, Hewer A, et al: Activation of tamoxifen and its metabolite a-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat, and mouse hepatocytes. Carcinogenesis 17:89-94, 1996
12. Martin EA, Rich KJ, White INH, et al: 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654, 1995
13. Phillips DH, Hewer A, Grover PL, et al: Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis 17:1149-1152, 1996
14. Carmichael PL, Ugwumadu AHN, Neven P, et al: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479, 1996
15. Hemminki K, Rajaniemi H, Lindahl B, et al: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56:4374-4377, 1996
16. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis 16:1299-1304, 1995
17. Tannenbaum SR: Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin Oncol 24:s1-81-s1-86, 1997 (suppl 1)
18. Hemminki K, Widlak P, Hou SM: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16:1661-1664, 1995
19. Jordan VC, Assikis VJ: Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin Cancer Res 1:467-472, 1995
20. Friedl A, Jordan VC: What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 31:27-39, 1994
21. Tomas E, Kauppila A, Blanco G, et al: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59:261-266, 1995
22. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995
23. Vogel CL, Shemano I, Schoenfelder J, et al: Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11:345-350, 1993
24. Stenbygaard LE, Herrstedt J, Thomsen JF, et al: Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial. Breast Cancer Res Treat 25:57-63, 1993
25. 8-cholestenol conversion to lathosterol in women with breast cancer. J Clin Oncol 13:2900-2905, 1995
26. Saarto T, Blomqvist C, Ehnholm C, et al: Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14:429-433, 1996
27. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
28. Love RR, Barden HS, Mazess RB, et al: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588, 1994
29. Twelves C, Harnett A: Advertisement for toremifene. Playing on women's fears is unethical. Br Med J 313:944-945, 1996 (letter)